Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lytix Biopharma AS (DE:6BG)
FRANKFURT:6BG
Lytix Biopharma AS (6BG) Stock Price & Analysis
0 Followers
6BG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.41 - €1.11
Previous Close€0.44
Volume0.00
Average Volume (3M)333.00
Market Cap
€18.42M
Enterprise Value€7.06M
Total Cash (Recent Filing)kr145.16M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)N/A
Beta0.66
Next Earnings
May 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume333
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
6BG FAQ
What was Lytix Biopharma AS’s price range in the past 12 months?
Lytix Biopharma AS lowest stock price was €0.41 and its highest was €1.11 in the past 12 months.
What is Lytix Biopharma AS’s market cap?
Currently, no data Available
When is Lytix Biopharma AS’s upcoming earnings report date?
Lytix Biopharma AS’s upcoming earnings report date is May 15, 2024 which is in 17 days.
How were Lytix Biopharma AS’s earnings last quarter?
Lytix Biopharma AS released its earnings results on Feb 29, 2024. The company reported -€0.039 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.039.
Is Lytix Biopharma AS overvalued?
According to Wall Street analysts Lytix Biopharma AS’s price is currently Overvalued.
Does Lytix Biopharma AS pay dividends?
Lytix Biopharma AS does not currently pay dividends.
What is Lytix Biopharma AS’s EPS estimate?
Lytix Biopharma AS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lytix Biopharma AS have?
Currently, no data Available
What happened to Lytix Biopharma AS’s price movement after its last earnings report?
Lytix Biopharma AS reported an EPS of -€0.039 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lytix Biopharma AS?
Currently, no hedge funds are holding shares in DE:6BG
---
Company Description
Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its lead product, LTX-315, is an oncolytic peptide with the potential to personalize immunotherapy.
---
Technical Analysis
---